Lead author Dr Joseph Sparano, of Montefiore Medical Centre in NY, said: "Any women with early stage breast cancer 75 or younger should have the test and discuss the results of TAILORx with her doctor".
"Until now, we've been able to recommend treatment for women with these cancers at high and low risk of recurrence, but women at intermediate risk have been uncertain about the appropriate strategy to take", study co-author Jeffrey Abrams, associate director of the National Cancer Institute's Cancer Therapy Evaluation Program, which supported the trial, said in the statement.
"The new results show that most women over 50, and who score within a given range, will not get any benefit from chemotherapy over and above hormonal therapy", Dr. Dana Abraham said, with Abraham Breast Clinic in Little Rock.
Following 10,273 women who had the most common type of breast cancer, researchers examined outcomes for the 69 per cent of patients who scored between 11 - 25 on the test.
The breast cancer study focused on cases where chemo's value increasingly is in doubt: women with early-stage disease that has not spread to lymph nodes, is hormone-positive (meaning its growth is fueled by estrogen or progesterone) and is not the type that the drug Herceptin targets.
They used her own immune cells against the disease, in a world first - never before has the treatment been used successfully in a woman with late stage breast cancer.
A United States woman with advanced breast cancer is healthy again after taking part in an experimental treatment, using her body's own immune system to wipe out the tumours. So they don't have to receive chemotherapy.
Baroness Delyth Morgan, chief executive of Breast Cancer Now, said: "It's fantastic news this landmark study could enable thousands more breast cancer patients over 50 to be safely spared gruelling chemotherapy".
The study, presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, is thought to be the largest breast cancer treatment trial ever conducted.
If the woman's score is 16 or higher and she is premenopausal, "then we're going to want to give her the chemotherapy", said Brawley. "These kinds of tools allow us to make tailored medicine a reality, allowing us to offer the right therapy for the right patient at the right time".
The researchers reported that for women younger than 50, results were similar to those of patients who had scores of 15 or lower. Of those women, 6,711 had test scores between 11 and 25, which placed them in the intermediate risk group.
A POTENTIAL cure for cancer may have been found in the USA after a woman suffering from an "incurable" breast cancer that had spread to some of her organs was cured of the killer illness.
A sample of the tumour is tested after surgery for 21 genetic markers, which indicate if it could grow and spread.
After nine years, 94 percent of both groups were still alive, and about 84 percent were alive without signs of cancer, so adding chemo made no difference.
Thousands of women now have that option thanks to a recent study revealing chemo isn't the only way to go. "It's exactly the sort of study that we need to make decisions about these genomic tests".
Still, he acknowledged that most patients with this form of advanced cancer will die within months, and "we need to do a lot more work".
Albain is excited to share the study results with her clients in her practice.
Professor Keane said the test will identify which women will benefit from endocrine (hormone) therapy only.